A therapy devised by Weizmann Institute immunologist Prof. Zelig Eshhar for the treatment of a specific kind of advanced blood cancer has shown tremendous results in an early-stage clinical trial led by researchers at the University of Pennsylvania’s Abramson Cancer Center and Perelman School of Medicine.